Market revenue in 2023 | USD 325.1 million |
Market revenue in 2030 | USD 778.0 million |
Growth rate | 13.3% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.07% in 2023. Horizon Databook has segmented the Asia Pacific head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The Asia Pacific market is expected to grow at a lucrative rate owing to the increasing prevalence of head & neck cancer, growing awareness about cancer treatment, rising disposable income, and increasing healthcare reforms.
Other factors contributing to market growth are improving healthcare infrastructure, increasing geriatric population, and rising number of local companies entering the market. Asia Pacific has a large population and a high prevalence of head and neck cancer.
According to an article published in the South Asian Journal of Cancer in January 2022, an estimated 57.5% of global head and neck cancer cases occur in Asia. Asia is the highest contributor of head and neck cancer cases globally.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific head and neck cancer therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account